drugset / Trial / NCT01518985

The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking

NCT01518985

Phase 1 Completed 6 enrolled Stealth BioTherapeutics Inc.
RandomizedCrossoverQuadruple-blindBasic science

Summary

This will be a phase 1 randomized, double-blind, 2-period, 2-sequence crossover trial enrolling 6 healthy volunteers to assess the impact of IV-administered Bendavia on the endothelial dysfunction induced by a single cigarette.

Timeline

Start
2012-01
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Elamipretide Peptide 0.25 mg/kg Intravenous

Indications

No indication recorded.